Needham & Company LLC Cuts Merit Medical Systems (NASDAQ:MMSI) Price Target to $101.00

Merit Medical Systems (NASDAQ:MMSI) had its price target lowered by analysts at Needham & Company LLC from $108.00 to $101.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the medical instruments supplier’s stock. Needham & Company LLC’s price target indicates a potential upside of 22.53% from the stock’s previous close.

Other equities analysts have also recently issued reports about the company. Zacks Research cut Merit Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Robert W. Baird set a $108.00 target price on shares of Merit Medical Systems in a report on Tuesday, December 16th. Canaccord Genuity Group boosted their price target on Merit Medical Systems from $93.00 to $99.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Piper Sandler lowered their price target on Merit Medical Systems from $113.00 to $106.00 and set an “overweight” rating for the company in a research report on Wednesday, February 18th. Finally, Barrington Research reiterated an “outperform” rating and issued a $106.00 price objective on shares of Merit Medical Systems in a research report on Friday, November 14th. Nine equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Merit Medical Systems has a consensus rating of “Moderate Buy” and a consensus price target of $104.89.

Merit Medical Systems Stock Performance

Merit Medical Systems stock opened at $82.43 on Wednesday. The firm has a fifty day simple moving average of $84.08 and a two-hundred day simple moving average of $84.98. The company has a quick ratio of 2.86, a current ratio of 4.28 and a debt-to-equity ratio of 0.48. Merit Medical Systems has a twelve month low of $77.62 and a twelve month high of $107.27. The company has a market capitalization of $4.89 billion, a PE ratio of 42.27, a P/E/G ratio of 2.22 and a beta of 0.61.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings data on Tuesday, February 24th. The medical instruments supplier reported $1.04 EPS for the quarter, topping the consensus estimate of $0.96 by $0.08. Merit Medical Systems had a return on equity of 14.27% and a net margin of 8.02%.The firm had revenue of $393.94 million for the quarter, compared to the consensus estimate of $390.77 million. During the same quarter in the previous year, the business earned $0.93 earnings per share. The company’s quarterly revenue was up 10.9% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Research analysts expect that Merit Medical Systems will post 3.37 EPS for the current year.

Institutional Investors Weigh In On Merit Medical Systems

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its holdings in shares of Merit Medical Systems by 7.3% during the 1st quarter. AQR Capital Management LLC now owns 16,361 shares of the medical instruments supplier’s stock valued at $1,730,000 after buying an additional 1,114 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Merit Medical Systems by 16.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 719,313 shares of the medical instruments supplier’s stock valued at $76,039,000 after acquiring an additional 103,878 shares during the period. State of New Jersey Common Pension Fund D boosted its stake in Merit Medical Systems by 6.0% during the second quarter. State of New Jersey Common Pension Fund D now owns 19,803 shares of the medical instruments supplier’s stock worth $1,851,000 after acquiring an additional 1,114 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in Merit Medical Systems by 5.3% in the second quarter. Envestnet Asset Management Inc. now owns 244,163 shares of the medical instruments supplier’s stock worth $22,824,000 after purchasing an additional 12,256 shares during the period. Finally, Whalen Wealth Management Inc. increased its stake in shares of Merit Medical Systems by 22.0% during the second quarter. Whalen Wealth Management Inc. now owns 4,755 shares of the medical instruments supplier’s stock valued at $445,000 after purchasing an additional 856 shares in the last quarter. 99.66% of the stock is owned by hedge funds and other institutional investors.

Key Merit Medical Systems News

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q4 results beat — EPS of $1.04 vs. consensus $0.96 and revenue of $393.9M vs. $390.8M; revenue grew ~10.9% year-over-year, with reported net margin ~8% and ROE ~14%. These metrics point to demand recovery and margin improvement. Merit Medical Systems Earnings Report
• Positive Sentiment: Upside FY2026 guidance — management raised full‑year EPS to $4.010–4.150 versus the prior consensus (~$3.73), implying stronger margin expansion and earnings growth for 2026. This is the main catalyst supporting the stock’s move higher. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analyst/press coverage detailing quarter and metrics — third‑party writeups (Zacks) confirm the beat and walk through key metric comparisons to estimates and prior year results; useful for due diligence but largely reiterative of company numbers. Merit Medical (MMSI) Q4 Earnings and Revenues Top Estimates
• Neutral Sentiment: Local/summary coverage — CT Post and other outlets published earnings snapshots summarizing the results and call; useful for quick read but unlikely to move the stock beyond the company-provided figures. Merit Medical: Q4 Earnings Snapshot
• Negative Sentiment: Price target trimmed — Needham’s Michael Matson kept a Buy rating but lowered the price target to $101, which signals more conservative near-term upside expectations despite the favorable results. That trimmed PT could cap immediate analyst-driven upside. Merit Medical Systems: Strong Q4 Beat, Upbeat 2026 Outlook…

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.